T-Cell Immunotherapy - Pipeline Analysis, 2016 - PowerPoint PPT Presentation

Loading...

PPT – T-Cell Immunotherapy - Pipeline Analysis, 2016 PowerPoint presentation | free to download - id: 893f69-NDAzN



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

T-Cell Immunotherapy - Pipeline Analysis, 2016

Description:

The study analyzed that the T-cell immunotherapy pipeline comprised of 139 therapeutic candidates in different stages of development. – PowerPoint PPT presentation

Number of Views:19

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: T-Cell Immunotherapy - Pipeline Analysis, 2016


1
T-Cell Immunotherapy Pipeline to Witness Huge RD
Investment In The Coming Years
2
T-Cell Immunotherapy Pipeline Analysis
According to a new research report Global T-Cell
Immunotherapy Pipeline Analysis, 2016 - Clinical
Trials Results, Patent, Designation,
Collaboration, and Other Developments published
by PS Market Research, the T cell immunotherapy
exhibits strong pipeline with estimated 139 drug
candidates in 2016.
T-cell immunotherapy pipeline in 2016
The study analyzed that the T-cell immunotherapy
pipeline comprised of 139 therapeutic candidates
in different stages of development. The high
prevalence of cancer across the globe fuels the
extensive research and development for the T-cell
immunotherapeutic. T-cell immunotherapy is
emerging as novel and promising approach for the
treatment of cancer. It is gaining huge traction
globally, for its several advantages over
conventional therapies such as very low or no
side effects and high specificity. Browse the
Report Summary at https//www.psmarketresearch.co
m/market-analysis/t-cell-immunotherapy-pipeline-an
alysis
3
T-Cell Immunotherapy Pipeline Analysis
Chimeric antigen receptors (CAR) T-cell is
majorly researched and developed, representing
75 T-cell immunotherapeutic candidates
CAR T-cells are the modified T-cells used to
express CARs, which recognize specific antigens
present on targeted cell. CARs are specifically
designed synthetic receptors, linked with the
single-chain variable fragment (scFV) of a
monoclonal antibody. The domain includes T-cell
receptor CD3-zeta chain, which graft specificity
into an immune effector cell. It mediates T-cell
cytotoxicity and activation when bound to a
target cell.
4
T-Cell Immunotherapy Pipeline Analysis
Strategic collaborations for the development of
T-cell immunotherapeutic
The research finds that the different companies
are collaborating for the development of T-cell
immunotherapeutic. In June 2015, Celgene
Corporation and Juno Therapeutics, Inc.
collaborated for the development and
commercialization of immunotherapies. Some of the
key players developing T-cell immunotherapies are
Novartis AG, Cellular Biomedicine Group, Inc.,
Kite Pharmaceuticals Inc. and others.
5
T-Cell Immunotherapy Pipeline Analysis
Download report sample at
https//www.psmarketresearch.com/market-analysis/t
-cell-immunotherapy-pipeline-analysis/report-sampl
e
6
GET IN TOUCH
THANK YOU!
For information regarding permissions and other
queries Kindly write to
US/Canada Toll-Free 1-888-778-7886
About PowerShow.com